ID   L-02
AC   CVCL_6926
SY   L02; LO2; HL-7702; HL7702; Liver-02; Human Liver-7702
DR   BTO; BTO:0005965
DR   ChEMBL-Cells; CHEMBL4295475
DR   ChEMBL-Targets; CHEMBL4296457
DR   GEO; GSM936770
DR   KCB; KCB 200511YJ
DR   PubChem_Cell_line; CVCL_6926
DR   TOKU-E; 3606
DR   Ubigene; YC-D004
DR   Wikidata; Q54900854
RX   PubMed=23498809;
RX   PubMed=23505090;
RX   PubMed=26116706;
RX   PubMed=26143199;
RX   PubMed=27027780;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   http://www.roche-applied-science.com/wcsstore/RASCatalogAssetStore/Articles/CustomerProtocol_X-tremeGENE%20HP_L02.pdf
WW   https://www.quora.com/How-does-the-L-02-cell-line-compare-with-the-TAMH-cell-line-How-closely-do-these-two-cell-lines-resemble-actual-human-hepatocytes
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00575.
CC   Population: African American.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): PubMed=26116706
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D21S11: 27,28
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 12
ST   D8S1179: 12
ST   FGA: 18,21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=23498809; DOI=10.1016/j.transproceed.2012.09.121;
RA   Hu X., Yang T., Li C., Zhang L., Li M., Huang W., Zhou P.;
RT   "Human fetal hepatocyte line, L-02, exhibits good liver function in
RT   vitro and in an acute liver failure model.";
RL   Transplant. Proc. 45:695-700(2013).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).
//
RX   PubMed=26143199; DOI=10.1016/j.jhazmat.2015.06.031;
RA   Cui R.-N., Zhang H.-X., Guo X.-J., Cui Q.-Q., Wang J.-S., Dai J.-Y.;
RT   "Proteomic analysis of cell proliferation in a human hepatic cell line
RT   (HL-7702) induced by perfluorooctane sulfonate using iTRAQ.";
RL   J. Hazard. Mater. 299:361-370(2015).
//
RX   PubMed=27027780; DOI=10.1007/s10565-016-9316-2;
RA   Wu Y., Geng X.-C., Wang J.-F., Miao Y.-F., Lu Y.-L., Li B.;
RT   "The HepaRG cell line, a superior in vitro model to L-02, HepG2 and
RT   hiHeps cell lines for assessing drug-induced liver injury.";
RL   Cell Biol. Toxicol. 32:37-59(2016).
//